export const accordianData = [
    {
        serviceOne: [
            {
                id: 1,
                title: "Lifecycle Management of ICSRs - From Triaging to Submission",
                content: "A Marketing Authorisation Holder has to ensure that any safety relevant information is evaluated properly, adequately and reported subsequently as an ICSR or SUSAR (Suspected Unexpected Serious Adverse Reaction). Complying with global regulatory requirements to fulfil this obligation remains the challenge. At Oviya MedSafe, our team consisting of physicians, scientists, pharmacists and medical data managers offer you our integrated solution for case management which comprises collection of safety relevant data by literature search, assessment of suspected ADRs from the literature, competent authorities and spontaneous reporting systems, followed by electronic reporting.",
            },
            {
                id: 2,
                title: "Aggregate Report Writing & Review (including but not limited to PSUR, PBRER, COD, PADER & DSUR)",
                content: "The recent past has seen Pharmacovigilance regulations becoming more stringent, placing various regulatory obligations on the Marketing Authorisation Holders. One of such stern obligations presses for more importance to be given to aggregate reports as these best help define the benefit-risk balance of medicinal products. Oviya MedSafe offers complete and customized support in preparing and reviewing aggregate reports. The Periodic Safety Update Reports, Periodic Adverse Drug Experience Reports, Periodic Benefit-Risk Evaluation Reports & Development Safety Update Reports, prepared by our staff, present the safety information in a remarkable way that easily endorses the proper evaluation of the Benefit-Risk profile. These reports are prepared according to ICH requirements and filed with regulatory agencies per their regulatory norms.",
            },
            {
                id: 3,
                title: "EU/UK QPPV and Local Responsible Person Services",
                content: "The European Economic Area requires its Marketing Authorisation Holders to appoint a European Union Qualified Person for Pharmacovigilance (EU QPPV) who will oversee the company’s Pharmacovigilance system. Acting as a central agent to fulfil all key functions, EU QPPV is required to have full understanding of all aspects of Pharmacovigilance. We at Oviya MedSafe provide European Union Qualified Person for Pharmacovigilance service through our adequately trained personnel. Our clients can be rest assured as we are committed to ensure this critical service is well met by our reliable and highly qualified experts. Under the European Union directives, national competent authorities may request the nomination of a contact person for Pharmacovigilance issues at national levels, reporting to the EU QPPV. Appointment of a Local Responsible Person and the scope of the role depends on the Pharmacovigilance setup of the Marketing Authorisation Holders. Oviya MedSafe can guide you with detailed information and assist you by deputing our Local Responsible Persons, for complying with the applicable regulatory requirements.",
            },
            {
                id: 4,
                title: "Risk Management Plans and REMS Services",
                content: "",
            },
            {
                id: 5,
                title: "Global and Local Literature Monitoring for PV",
                content: "",
            },
            {
                id: 6,
                title: "Signal Detection, Assessment, and Management",
                content: "",
            },
            {
                id: 7,
                title: "Clinical Trial Safety Management",
                content: "",
            },
        ],
        serviceTwo:[
            {
                id: 1,
                title: "Development of SOPs, Work Instructions, and Guides",
                content: "Generation of well-structured written policies and procedures ensures effective implementation of quality system and demonstrates what the MAH wants to achieve. At Oviya MedSafe, we develop all Pharmacovigilance-related Standard Operating Procedures (SOPs) in compliance with global regulatory requirements safeguarding data integrity and keeping quality standards. We also extend our service by providing guidance with revising and updating existing procedures.",
            },
            {
                id: 2,
                title: "Audit & Inspection Preparation, Readiness, and Support",
                content: "The recently released Pharmacovigilance regulations have insisted that all MAH in the EEA to perform regular risk based audits of their Pharmacovigilance system and Quality Management Systems and to communicate any safety risks with regulators and health professionals. The main purpose of a Pharmacovigilance audit is to verify the effectiveness and appropriateness of the Pharmacovigilance system using the objective evidence. The team at Oviya MedSafe offers expert advice and support related to audits and mock inspections to ensure your company is well prepared to manage the risks that have a huge impact to the company’s Pharmacovigilance and Quality management system which might lead to favourable regulatory Pharmacovigilance inspection outcomes.",
            },
            {
                id: 3,
                title: "Training and Development of Client Staff",
                content: "The rapidly changing regulatory environment further challenges the need for Pharmacovigilance. With consultancy as our core business, we offer to provide comprehensive and up-to-date training to your staff. With strong sense of industrial trends and regulatory expectations, we can help guide you through the strategic planning the earliest stages of setting up the Pharmacovigilance system.",
            },
            {
                id: 4,
                title: "Development and Maintenance of PV QMS",
                content: "",
            },
            {
                id: 5,
                title: "Preparation and Maintenance of PSMF",
                content: "",
            },
            {
                id: 6,
                title: "Transformational Pharmacovigilance Support, Leveraging Technology and AI initiatives",
                content: "",
            },
            {
                id: 7,
                title: "Strategic Deployment of Contract Staff",
                content: "",
            },
        ],
    },
    {

    }

];